Search
-
The Rising Tide of Private Labels: How name brands can stay afloat
By embracing innovation, building strong brand equity, enhancing the customer experience, and adopting strategic partnerships and omnichannel strategies, name brands can thrive in the face of competition.
-
Synthetic Data: From Hype to Reality - A Guide to Responsible Adoption
Synthetic data, powered by AI, is poised to transform the market research industry. The question isn’t if, but when and how. Recognizing the potential, but also the possible pitfalls, of the issue, our clients asked us to provide Ipsos’ trusted perspective on the topic.
-
Humanizing AI: Real human data to generate and predict real innovation success
Unlock the secrets of innovation success with AI by infusing models with real human data, as 'Humanizing AI' reveals the pivotal role authentic interactions play in predicting the next big thing.
-
ChatGPT and the rise of generative AI: navigating the changing landscape of AI
While the domain of Generative Artificial Intelligence (AI) has been growing in recent years, ChatGPT accelerated its adoption and broke through as the first “mass” Generative AI application. It is important to take notice and put this and other emerging tools in perspective as the implications of the technologies will be far reaching and very fast.
-
Choosing the right AICI platform
Four criteria for picking the right consumer insights tool for your organization.
-
Future of Insights
Ipsos’ Future of Insights series examines the various ways the insight function is transforming and how to elevate its impact.
-
Building the business case for AI-enabled consumer intelligence
Social listening 2.0 is here. AI-enabled consumer intelligence solutions enable market research and insights pros to spot trends and stay ahead of the market.
-
Harnessing the Power of Data
The third paper in our “Future of Insights” series explores how organisations are evolving to harness the power of data and technology for better insights.
-
Multi-source healthcare data
The world of pharma business insight is likely to change as it embraces a multi-data source reality.